Viet Reader.

Loading...

Viet Reader.

VR.

Premier Newspaper for Vietnamese Worldwide

PR Newswire

Image: WuXi Biologics Reports Strong Profitable Growth in H1 2026

WuXi Biologics Reports Strong Profitable Growth in H1 2026

Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD) IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds EBITDA grew 3.5% YoY and

Image: Fosun Pharma Announces 2026 Interim Results

Fosun Pharma Announces 2026 Interim Results

Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half